BR112023020826A2 - Cocristais de upadacitinibe - Google Patents

Cocristais de upadacitinibe

Info

Publication number
BR112023020826A2
BR112023020826A2 BR112023020826A BR112023020826A BR112023020826A2 BR 112023020826 A2 BR112023020826 A2 BR 112023020826A2 BR 112023020826 A BR112023020826 A BR 112023020826A BR 112023020826 A BR112023020826 A BR 112023020826A BR 112023020826 A2 BR112023020826 A2 BR 112023020826A2
Authority
BR
Brazil
Prior art keywords
cocrystals
upadacitinib
compound
disclosure relates
pyrazin
Prior art date
Application number
BR112023020826A
Other languages
English (en)
Inventor
Alessandra Mattei
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112023020826A2 publication Critical patent/BR112023020826A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

cocristais de upadacitinibe. a revelação refere-se a cocristais de formas de estado sólido de (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]-pirazin-8-il)-n -(2,2,2-trifluoroetil)pirrolidina-1-carboxamida (composto 1). especificamente, a presente revelação refere-se a cocristais do composto 1 e a um coformador adequado, como um ácido benzoico substituído.
BR112023020826A 2021-04-07 2022-04-07 Cocristais de upadacitinibe BR112023020826A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163171855P 2021-04-07 2021-04-07
PCT/US2022/071596 WO2022217257A1 (en) 2021-04-07 2022-04-07 Cocrystals of upadacitinib

Publications (1)

Publication Number Publication Date
BR112023020826A2 true BR112023020826A2 (pt) 2023-12-12

Family

ID=83546642

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020826A BR112023020826A2 (pt) 2021-04-07 2022-04-07 Cocristais de upadacitinibe

Country Status (8)

Country Link
US (1) US20240043434A1 (pt)
EP (1) EP4319743A1 (pt)
JP (1) JP2024514820A (pt)
KR (1) KR20230167057A (pt)
AU (1) AU2022255047A1 (pt)
BR (1) BR112023020826A2 (pt)
CA (1) CA3216378A1 (pt)
WO (1) WO2022217257A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101785257B1 (ko) * 2009-12-01 2017-10-16 애브비 인코포레이티드 신규한 트리사이클릭 화합물
CN108368121B (zh) * 2015-10-16 2023-01-13 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物的方法
WO2020177645A1 (zh) * 2019-03-01 2020-09-10 苏州科睿思制药有限公司 一种Upadacitinib的晶型及其制备方法和用途
WO2020224633A1 (zh) * 2019-05-09 2020-11-12 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法

Also Published As

Publication number Publication date
KR20230167057A (ko) 2023-12-07
WO2022217257A1 (en) 2022-10-13
EP4319743A1 (en) 2024-02-14
US20240043434A1 (en) 2024-02-08
AU2022255047A1 (en) 2023-10-19
CA3216378A1 (en) 2022-10-13
JP2024514820A (ja) 2024-04-03

Similar Documents

Publication Publication Date Title
AU2016340167A8 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ECSP11011182A (es) Compuestos orgánicos
CR20110312A (es) Compuestos orgánicos
EA201190205A1 (ru) ПОЛЕЗНЫЕ ФАРМАЦЕВТИЧЕСКИЕ СОЛИ 7-[(3R,4R)-3-ГИДРОКСИ-4-ГИДРОКСИМЕТИЛПИРРОЛИДИН-1-ИЛМЕТИЛ]-3,5-ДИГИДРОПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНА
CO6602133A2 (es) Derivados de i,idazo(1,2-a)pirazina y su uso para la prevencion o tratamiento de trastornos y enfermedades neurologicas, siquiatricas y metabolicas
ECSP066473A (es) 42-ester de rapamicina amorfo con el ácido 3-hidroxi-2-(hidroximetil)-2-metil propiónico y las composiciones farmaceúticas que contienen el mismo
CO7170182A2 (es) Derivados de 2,2-difluoropropinamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos
AU2011288503A8 (en) 6-Cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
AR084050A1 (es) Acidos indaniloxidihidrobenzofuranilaceticos
EP2698160A3 (en) Organic compounds
CL2011001361A1 (es) Compuestos derivados de n-(imidazo[1,2-a]pirazin-8-il)-1h-amina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades mediadas por inhiibicion de actividad syk, tales como cancer, trastornos alergicos o inflamatorios.
CL2012002500A1 (es) Composición que comprende: 1) (2r,6s,13as,14ar,16as,z)-n-(ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5-16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-14a-carboxamida, 2)polímero hidrofílico y 3)agente tensioactivo; proceso para elaborar.
WO2009129545A8 (en) Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
SG173374A1 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
MX352831B (es) Cristales de sal.
AR059937A1 (es) Compuesto de pirido (2,3-d) pirimidin -7-ona o compuesto que contiene 3,4- dihidropirimido (4,5-d) pirimidin -2 (1h) -ona y proceso para su preparacion
UY29221A1 (es) Derivados de octahidropirrolo(3,4-c)pirrol
BR112015007503A2 (pt) derivados de oxazolina terapeuticamente ativos
BR112015032132A2 (pt) cristais de base livre
BR112023020826A2 (pt) Cocristais de upadacitinibe
PE20070403A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE CEFEPIME Y DERIVADOS DE 6-ALQUILIDEN-PENEM BICICLICOS COMO INHIBIDORES DE ß-LACTAMASA
DE602005025036D1 (de) Verfahren zur herstellung von imidazopyridinen
AR082054A1 (es) Derivados aril- y heteroarilamida como inhibidor de enzima pde10a
PE20070342A1 (es) 6-ALQUILIDEN-PENEM TRICICLICOS COMO INHIBIDORES DE ß-LACTAMASA Y COMBINACION DE ANTIBIOTICOS DE ß-LACTAMA: UN ANTIBIOTICO DE AMPLIO ESPECTRO
DK2038288T3 (da) 4-amino-3-(azolylphenoxymethyl)thieno[3,2]pyridin-7-carboxylsyrederivater